Please login to the form below

Not currently logged in
Email:
Password:

biosimilar

This page shows the latest biosimilar news and features for those working in and with pharma, biotech and healthcare.

Novartis sells off part of Sandoz portfolio

Novartis sells off part of Sandoz portfolio

Novartis sells off part of Sandoz portfolio. Swiss pharma giant will retain biosimilars. ... Francis adds: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics,

Latest news

More from news
Approximately 129 fully matching, plus 300 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • Biosimilars: Getting the flock to market

    The factor that drives the success of biosimilars is value. The biosimilar dividend is that more patients can get access to the high-value treatments they need. ... Luckily, the biosimilar path has already been trodden, so new agents can slipstream the

  • Webinar: What next for biosimilars?

    Webinar: What next for biosimilars? Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST. ... Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and

  • Video: Global Biosimilars Market

    Video: Global Biosimilars Market. Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch. ... It is predicted that

  • Tackling biosimilars – how to handle the threat to Pharma brands

    Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars. ... Therefore, while the biosimilar drugs may be very similar, they will never be identical.

  • Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

    Free Thinking: Are biosimilars the answer to the rising cost of RA treatment? ... With Enbrel biosimilar Benepali about to launch across EU, we ask what’ s next for RA?

More from PMHub
Approximately 17 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics